Navigation Links
New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
Date:4/23/2008

UPPSALA, Sweden and CAMBRIDGE, England, April 23 /PRNewswire/ -- Two leading companies in the area of fragment-based drug discovery (FBDD) today announced a new commercial alliance. IOTA Pharmaceuticals Ltd, based in Cambridge, UK, and Beactica AB, based in Uppsala, Sweden, will join forces to deploy a proprietary FBDD-based lead discovery and optimization platform.

The IOTA-Beactica platform couples comprehensive, site-directed FBDD libraries to state-of-the-art fragment and lead screening using surface plasmon resonance (SPR) biosensor technology, enabling the rapid progression of new discovery programs from concept to optimized lead.

Based on rapid determination of ligand-target interaction information, and using a unique combination of fragment-based drug screening and medicinal chemistry-led design approaches, applicable to a wide range of new targets, the platform will initially focus on the development of new classes of kinase inhibitors. The reagents, tools and technologies developed by the two companies will be commercialized through drug discovery partnerships with pharmaceutical companies active in the kinase area.

Dr Per Kallblad, CEO of Beactica, said, "We are delighted to work with IOTA to expand our existing drug discovery platform. The combination of IOTA's proprietary FBDD engine with Beactica's SPR screening technology will be an excellent way to pursue the discovery and optimization of new kinase inhibitors."

Dr David Bailey, heading IOTA, commented, "Fragment-based drug discovery is a fast, efficient and productive route to NCE discovery. Our combined technologies offer a comprehensive lead discovery solution to our pharma partners."

About IOTA

IOTA Pharmaceuticals provides FBDD-based molecular design, compound screening and lead discovery services to its partners in the pharmaceutical industry. For more information about IOTA, please visit http://www.iotapharma.com

About Beactica

Beactica is a specialist drug discovery company, utilizing its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. For more information about Beactica, please visit http://www.beactica.com

Contacts

Dr David Bailey, CEO IOTA

david.bailey@iotapharma.com

Dr Per Kallblad, CEO Beactica

per.kallblad@beactica.com


'/>"/>
SOURCE IOTA Pharmaceuticals Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
2. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
3. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
4. Progen Restructures Manufacturing and Drug Discovery Divisions
5. Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool
6. Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery
7. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
8. BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services
9. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
10. Contract Services for Big Pharma and Biotechs Driving Growth and Innovation from Discovery to Clinical Trials
11. Xenon Announces Appointment of VP, Discovery Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... used in spinal surgical procedures, today announced the completion of a significant transaction ... for current and future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), ...
(Date:4/29/2016)... , April 29, 2016 ... by Transparency Market Research "Separation Systems for Commercial ... Growth, Trends, and Forecast 2015 - 2023", the ... at US$ 10,665.5 Mn in 2014 and is ... from 2015 to 2023 to reach US$ 19,227.8 ...
(Date:4/29/2016)... ... 29, 2016 , ... During a two day program for ... company, CereScan’s CEO, John Kelley, joined other Denver business leaders in providing business ... the Denver area business community, shared his top fundamental learnings in building an ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Summit ... (NSCF) to support the development of a patient-specific stem cell therapy for the treatment ... the lab of Dr. Jeanne Loring at The Scripps Research Institute in San Diego, ...
Breaking Biology Technology:
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):